IMMUNIC, INC. (IMUX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '13: -4.9M Q2 '13: -7.1M Q3 '13: -9.2M Q4 '13: -10.2M Q1 '14: -11.9M Q2 '14: -11.6M Q3 '14: -12.8M Q4 '14: -14M Q1 '15: -14.8M Q2 '15: -15.1M Q3 '15: -12.3M Q4 '15: -9.9M Q1 '16: -9.7M Q2 '16: -9.5M Q3 '16: -10.2M Q4 '16: -11.8M Q1 '17: -12.7M Q2 '17: -12.5M Q3 '17: -12.6M Q4 '17: -14.8M Q1 '18: -14.5M Q2 '18: -2.7M Q3 '18: -1.8M Q4 '18: 7M Q1 '19: -4.7M Q2 '19: -15M Q3 '19: -9.2M Q4 '19: -8.2M Q1 '20: -9M Q2 '20: -12.2M Q3 '20: -13.5M Q4 '20: -14.2M Q1 '21: -32.4M Q2 '21: -19.2M Q3 '21: -18.4M Q4 '21: -21.7M Q1 '22: -21.4M Q2 '22: -20.6M Q3 '22: -20.1M Q4 '22: -57.3M Q1 '23: -27.3M Q2 '23: -25M Q3 '23: -23.6M Q4 '23: -23.4M Q1 '24: -23.9M Q2 '24: -22.8M Q3 '24: -25.7M Q4 '24: -25.6M Q1 '25: -26.8M Q2 '25: -27.1M Q3 '25: -26M Q4 '25: -23.3M Q1 '26: -33.2M Q2 '26: -35.3M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '13: -10.3M Q2 '13: -7.3M Q3 '13: -7M Q4 '13: -10.2M Q1 '14: -10.7M Q2 '14: -10.2M Q3 '14: -12.8M Q4 '14: -14M Q1 '15: -14.8M Q2 '15: -15.1M Q3 '15: -12.3M Q4 '15: -9.9M Q1 '16: -9.6M Q2 '16: -9.5M Q3 '16: -10.2M Q4 '16: -11.7M Q1 '17: -12.6M Q2 '17: -12.4M Q3 '17: -12.5M Q4 '17: -14.6M Q1 '18: -2.3M Q2 '18: -2.7M Q3 '18: -1.8M Q4 '18: -4.8M Q1 '19: -4.3M Q2 '19: -14.7M Q3 '19: -8.2M Q4 '19: -7.7M Q1 '20: -8.5M Q2 '20: -11.5M Q3 '20: -12.9M Q4 '20: -11.2M Q1 '21: -34.5M Q2 '21: -17.9M Q3 '21: -19.3M Q4 '21: -21.2M Q1 '22: -20.8M Q2 '22: -21.9M Q3 '22: -21.2M Q4 '22: -56.5M Q1 '23: -25.3M Q2 '23: -24M Q3 '23: -22.8M Q4 '23: -21.6M Q1 '24: -29.6M Q2 '24: -21.4M Q3 '24: -24.4M Q4 '24: -25.2M Q1 '25: -25.5M Q2 '25: -26.8M Q3 '25: -25.6M Q4 '25: -19.3M Q1 '26: -32.6M Q2 '26: -34.1M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '13: -4.6M Q2 '13: -5.9M Q3 '13: -8.1M Q4 '13: -10.1M Q1 '14: -9.4M Q2 '14: -9.9M Q3 '14: -11.2M Q4 '14: -10.4M Q1 '15: -13.5M Q2 '15: -15.1M Q3 '15: -12M Q4 '15: -9.3M Q1 '16: -10M Q2 '16: -8.8M Q3 '16: -7.9M Q4 '16: -9.1M Q1 '17: -10.9M Q2 '17: -10.2M Q3 '17: -9.4M Q4 '17: -9.9M Q1 '18: -13.1M Q2 '18: 8.9M Q1 '19: -5.3M Q2 '19: -11M Q3 '19: -6M Q4 '19: -6.3M Q1 '20: -11M Q2 '20: -9.2M Q3 '20: -11.9M Q4 '20: -14M Q1 '21: -12.9M Q2 '21: -29M Q3 '21: -17.6M Q4 '21: -23.7M Q1 '22: -20.7M Q2 '22: -15.8M Q3 '22: -13.6M Q4 '22: -15.1M Q1 '23: -19.5M Q2 '23: -20M Q3 '23: -17.3M Q4 '23: -14M Q1 '24: -24M Q2 '24: -17M Q3 '24: -20.8M Q4 '24: -23M Q1 '25: -21.8M Q2 '25: -24.6M Q3 '25: -20.1M Q4 '25: -19.3M Q1 '26: -17.3M Q2 '26: -31M Q3 '13 Q2 '15 Q1 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '13: -4.7M Q2 '13: -6.3M Q3 '13: -8.7M Q4 '13: -10.4M Q1 '14: -10.2M Q2 '14: -10.1M Q3 '14: -11.5M Q4 '14: -10.4M Q1 '15: -14.2M Q2 '15: -16.4M Q3 '15: -12.3M Q4 '15: -9.3M Q1 '16: -10.1M Q2 '16: -8.9M Q3 '16: -8.2M Q4 '16: -9.2M Q1 '17: -11.2M Q2 '17: -10.3M Q3 '17: -9.6M Q4 '17: -10M Q1 '18: -13.2M Q2 '18: 8.7M Q1 '19: -5.3M Q2 '19: -11M Q3 '19: -6M Q4 '19: -6.3M Q1 '20: -11M Q2 '20: -9.3M Q3 '20: -12M Q4 '20: -14M Q1 '21: -13M Q2 '21: -29M Q3 '21: -17.6M Q4 '21: -23.7M Q1 '22: -20.7M Q2 '22: -15.8M Q3 '22: -13.7M Q4 '22: -15.1M Q1 '23: -19.6M Q2 '23: -20M Q3 '23: -17.4M Q4 '23: -14.2M Q1 '24: -24M Q2 '24: -17.2M Q3 '24: -20.8M Q4 '24: -23M Q1 '25: -21.8M Q2 '25: -24.6M Q3 '25: -20.2M Q4 '25: -19.3M Q1 '26: -17.3M Q2 '26: -31.2M Q3 '13 Q2 '15 Q1 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '18: 42.4M Q1 '19: 43.7M Q1 '21: 21.2M Q2 '21: 21.7M Q3 '21: 25.3M Q1 '22: 28.1M Q2 '22: 30.2M Q3 '22: 30.6M Q1 '23: 43.7M Q2 '23: 44.4M Q3 '23: 44.6M Q1 '24: 97.3M Q2 '24: 101.3M Q3 '24: 101.3M Q1 '25: 10.1M Q2 '25: 13.2M Q3 '25: 193.9M Q1 '26: 30.1M Q2 '26: 42.5M Q1 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-90.00 -60.00 -30.00 0.00 30.00 60.00 90.00 Q4 '13: -75.03 Q1 '14: -77.41 Q2 '14: -63.99 Q3 '14: -48.27 Q4 '14: -26.58 Q1 '15: -2.71 Q2 '15: -2.43 Q3 '15: -2.35 Q4 '15: -2.10 Q1 '16: -1.79 Q2 '16: -1.46 Q3 '16: -1.27 Q4 '16: -1.30 Q1 '17: -1.38 Q2 '17: -1.37 Q3 '17: -1.35 Q4 '17: -1.33 Q1 '20: -3.88 Q2 '20: -3.26 Q3 '20: -3.14 Q4 '20: -2.92 Q1 '21: -3.76 Q2 '21: -3.68 Q3 '21: -3.74 Q4 '21: -4.02 Q1 '22: -3.13 Q2 '22: -3.03 Q3 '22: -2.96 Q4 '22: -3.77 Q1 '23: -3.61 Q2 '23: -3.43 Q3 '23: -3.25 Q4 '23: -2.11 Q1 '24: -1.83 Q2 '24: -1.50 Q3 '24: -1.23 Q4 '24: -1.00 Q1 '25: -3.21 Q2 '25: -5.03 Q3 '25: -4.92 Q4 '25: -0.62 Q1 '26: 0.81 Q2 '26: 2.04 Q4 '13 Q2 '15 Q4 '16 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.